Pre Clinical Services

In preclinical development, the quality, speed, and cost of your studies directly influence your ability to attract investment and reach the clinical stage.

That’s why many companies turn to India’s highly skilled scientists and world‑class CROs – delivering studies at significant cost savings and higher speed, due to the large talent pool in India, all the while being consistent with the requirements of the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other global regulators. 

Amritt can connect you to vetted partners in India that conduct both GLP and Non-GLP studies and services such as:

• Target and Lead Identification
• Drug Discovery
• ADME Assays
• Genotoxicity Studies
• DART Studies
• Structure Activity Relationships

We have a proven track record in not only identifying but also actively managing relationships with CROs specializing in:

• Investigational New Drug (IND) enabling studies
• 505(b)(2) pathways to support your New Drug Application (NDA)

Our partners operate facilities approved by global standards organizations and staffed by seasoned professionals serving North American and European clients. They bring deep expertise in discovery chemistry, analytical and bioanalytical services, pharmacokinetics, toxicokinetics, dose‑range finding, and more.

Schedule a 30‑minute call to explore how you can cut your costs by up to 50%. Let’s discuss your preclinical needs and how you can start benefiting from India’s proven talent, infrastructure, and cost‑effective innovation.

With two decades of experience guiding global biopharma companies, Amritt helps you identify the right partners, accelerate timelines, and maximize the value of your preclinical pipeline. When you work with us, we manage the relationship with your preclinical CRO from start to finish – so you can focus on scientific progress rather than logistics.